Cancer therapeutics using survivin birc5 as a target: what can we do after over two decades of study?

HIGHLIGHTS

• who: Fengzhi Li from the (UNIVERSITY) have published the article: Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?, in the Journal: (JOURNAL)
• what: Just prior to submission of this article, a new small_molecule PZ-6-QN (Fig 1i) was identified, and shown to bind survivin similarly to the known Smac peptide, AVPI . This approach has led to promising survivin dimerization modulators. Survivin-2B80-88 Following their initial finding , the survivin-2B80-88 (AYACNTSTL) vaccination-based phase I clinical study was conducted to assess patients with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.